chartexchange

Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union

GlobeNewswire Inc. | Nov 13, 2026 6:26 AM EST

European Commission to make final decision on arimoclomol MAA following negative CHMP opinion European Commission to make final decision on arimoclomol MAA following negative CHMP opinion

Read original article